Chai Discovery's Bitter Lesson: Drug Design Is Another Scaling Problem

Drug discovery is shifting from a serendipitous, trial-and-error process toward a rigorous, engineering-based discipline powered by AI. By applying scaling laws—scaling data, models, and compute—Chai Discovery aims to create a computer-aided design suite for molecules that enables researchers to specify therapeutic properties upfront. This approach has significantly improved antibody design, increasing binding success rates from 0.1% to 15% and allowing for the targeting of previously "undruggable" proteins. Rather than building a closed drug pipeline, the company functions as an infrastructure provider, partnering with major pharmaceutical firms to iterate on models through real-world validation. This strategy ensures that models remain generalizable and robust, ultimately accelerating the development of precise, effective medicines while maintaining high standards for scientific verification.